1. Generics Bulletin
  2. >>Business

China Beckons: Sun Joins Indian Firms Priming For Larger Presence

 
• By Anju Ghangurde

Evolving regulations and emerging opportunities appear to have put China firmly on the radar of several frontline Indian firms. Sun Pharma is the latest to join those seeking a larger play in the Asian market.

China and India flags
INDIAN FIRMS ARE KEEN ON A LARGER PRESENCE IN CHINA

More Indian companies appear to be lining up to vie for a share of the Chinese market amid evolving regulations there that encourage innovation and speed up drug approvals, but also place an equal emphasis on quality and reining in costs.

India’s top ranked drug firm, Sun Pharmaceutical Industries Ltd., has now indicated its intent to tap into the China...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

Xbrane Sets Date For Latest Run At Ranibizumab In US

 
• By Dave Wallace

After a series of setbacks for its Lucentis (ranibizumab) biosimilar filing in the US, Xbrane Biopharma now has a fresh action date from the FDA – although any approval will be contingent on a successful agency reinspection of its manufacturing sites.

Zydus Strikes Landmark $141m Agreement To Break Into Global CDMO Business

 
• By Dean Rudge

Zydus Lifesciences said it would be able to leverage supply chain dynamics and a “favorable geopolitical environment” to expand its reach in the US and globally as it penned a trio of agreements to plant its flag in the global CDMO space.

Dr Reddy’s And Alvotech Team Up On Keytruda Rival

 
• By Dave Wallace

After previously partnering on denosumab, Alvotech and Dr Reddy’s have announced a further alliance to co-develop a biosimilar version of Keytruda (pembrolizumab).

Formycon And Fresenius Launch Partnered Stelara Rival In Canada

 
• By Adam Zamecnik

Several years after the initial signing of their agreement, Formycon and Fresenius Kabi announced the launch of their Stelara biosimilar Otulfi in Canada, adding another key market to their list.

More from Generics Bulletin